For researchers interested in reconstitution and preparation, mazdutide follows similar handling requirements to other peptide-based GLP-1 agonists
Patients with T2DM experience a significant decline in the incretins functional properties which causes delayed and reduced insulin release after glucose administration and impairs glucose tolerance [12,13,14]
Currently, the FDA guidelines state that to be considered for a GLP-1 agonist, individuals must have: A BMI of 30 or greater OR A BMI of 27 or greater with at least one weight-related comorbidity (i.e
We sat down with That Clean Life member Prabhsimran Saini, RD, MHSc, CDE, who is an expert in diabetes nutrition and working with GLP-1 medications, to talk about how she approaches meal planning for these clients
Potential side effects and tolerance are another critical consideration